Cyclacel Pharmaceuticals – Cell Cycle Inhibitor Study in Solid and Blood Cancers

Returning guest, Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, a veteran of the industry and a developer of novel therapies that target various phases of cell cycle control for the treatment of cancer, shares an update on the dose escalation study of Fadraciclib in solid and blood cancers. 

Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has over 35 years at three public biotechs and two pharmas. He participated in in-licensing, clinical development, regulatory approval, partnering, and commercial launch of several drugs, mainly in inflammation and hematology/oncology, including Abelcet ®, Evacet/Myocet ®, ProHance ®, Remicade ®, and Reopro ®. Major functional roles included international operations and business development as Vice President at Liposome (subsequently acquired by Elan) and previously Vice President in the pharmaceuticals division of Bristol-Myers Squibb. He began his career in the early ’80s, after training at Novartis, as one of the first employees of Centocor (subsequently acquired by Johnson & Johnson). He holds an MBA and MPH (Hospital & Health Services Management) with honors, Kellogg School of Management, Northwestern University, and a BA, Williams College. He serves on the Board of Trustees of BioNJ, the NJ biotech association.